Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05032040 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 7, 2025 (before its estimated October 15, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 17 of 17 sitesv10 Show 1 more changeShow less
    • Site details revised at 17 of 17 sites
  2. Primary completion date: Mar 15, 2025 to Oct 15, 2025 Primary endpoint revised · Enrollment target: 150 to 170 · Study sites: 12 to 17 · 3 morev9 Show 6 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 150 to 170
    • Study sites: 12 to 17
    • Completion date: May 30, 2025 to Dec 30, 2025
    • Eligibility criteria expanded, about 6 words
    • Study description expanded, about 25 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv8
  4. Primary completion date: Jul 31, 2023 to Mar 15, 2025 Study sites: 11 to 12 · Completion date: Aug 31, 2023 to May 30, 2025v7 Show 2 more changesShow less
    • Study sites: 11 to 12
    • Completion date: Aug 31, 2023 to May 30, 2025
  5. Study sites: 8 to 11v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 3 to 8v5
  2. Interventions: XmAb20717 (Biological) to vudalimab (Biological) Eligibility criteria revised · Study description revised · Study title revisedv4 Show 3 more changesShow less
    • Eligibility criteria revised
    • Study description revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date: Apr 30, 2022 to Jul 21, 2022 · Study sites: 0 to 3v3 Show 2 more changesShow less
    • Start date: Apr 30, 2022 to Jul 21, 2022
    • Study sites: 0 to 3
  4. Start date: Dec 31, 2021 to Apr 30, 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xencor
10 trials monitored
See all monitored trials
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
Ovarian Cancer
1,245 trials monitored
See 80 trials at risk
Cervical Cancer
859 trials monitored
See 43 trials at risk
and 1 more disease
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Trial Details
NCT Number NCT05032040
Lead Sponsor Xencor, Inc.
Collaborators: ICON plc
Conditions Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov